Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Pegylated Liposomal Doxorubicin In Patients With Metastatic Triple-negative Breast Cancer: 8-year Experience Of A Single Center

S. Khallaf, Jasmine Roshdy, Abeer Ibrahim
Published 2020 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
The known efficacy of doxorubicin in metastatic breast cancer is countered by its dose-limiting myelosuppression and cardiotoxicity. Pegylated liposomal doxorubicin (PLD) was discovered to overcome these problems. But the data regarding its use in metastatic TNBC (triple-negative breast cancer) is still insufficient. Our study aimed to assess the factors affecting the outcome of the patients with metastatic TNBC who received PLD. During a period of 8 years (January 2011–December 2018), we analyzed 39 eligible patients. The disease control rate (DCR) was 51.3%. Among all the analyzed factors, two of them significantly affected DCR. The first factor was the chemosensitivity to prior anthracycline. As patients with chemosensitive disease had higher DCR than those with the chemoresistant disease (P = .001). The second factor was the number of prior lines of chemotherapy. As the patients who received two prior lines had a higher DCR than those who received three lines or more (P = .023). Chemosensitivity was the only significant independent factor for DCR (odds ratio = .095, P = .008). For the studied patients, the median progression-free survival (PFS) was 7 months. The anthracycline-chemosensitivity was the only significant independent prognostic factor for PFS (P = .002). The median overall survival (OS) was 12 months. There was a marginally significant effect of anthracycline-chemosensitivity on OS (P = .052). The anthracycline-chemosensitivity is an independent predictive and prognostic factor for the patients with metastatic TNBC receiving PLD. In developing countries, PLD should be reserved for the patients whose tumors are anthracycline-chemosensitive.
This paper references
A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study
N. Harbeck (2016)
IBM Corp (2012)
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E. Eisenhauer (2009)
Histological Grading and Prognosis in Breast Cancer
H. Bloom (1957)
v1.0. Cancer incidence and mortality worldwide: IARC
J Ferley (2012)
Anthracycline Chemotherapy and Cardiotoxicity
John Mcgowan (2016)
A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
J. Huober (2009)
Released. IBM SPSS Statistics for Windows, Version 21.0. Armonk: IBM
Ibm Corp (2012)
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxanerefractory advanced breast cancer
AM Keller (2004)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
H. O'Sullivan (2019)
Liposomal anthracyclines in metastatic breast cancer: clinical update.
E. Rivera (2003)
Stratifying triple-negative breast cancer: which definition(s) to use?
B. Adamo (2011)
Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial
M. Fiegl (2011)
How I treat metastatic triplenegative breast cancer
R Caparica (2019)
Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis
S. Rafiyath (2012)
Advances in the use of PARP inhibitor therapy for breast cancer
K. McCann (2018)
Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence
R. Dent (2007)
Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens.
R. A'hern (1993)
Efficacy and Cardiotoxicity of Liposomal Doxorubicin-Based Chemotherapy in Advanced Breast Cancer: A Meta-Analysis of Ten Randomized Controlled Trials
Meiyuan Xing (2015)
How I treat metastatic triple-negative breast cancer
R. Caparica (2019)
National Cancer Institute-Common Toxicity Criteria Adverse Events Versions
Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther
J V Mcgowan (2017)
A unified definition of clinical anthracycline resistance breast cancer
X. Pivot (2000)
Outcomes of systemic therapy for advanced triple-negative breast cancer: A single centre experience.
N. Battisti (2018)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
J. Ferlay (2010)
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.
Alan M. Keller (2004)
Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.
P. Barrett-Lee (2009)
Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long‐term results from a single institution experience
P. Martin-Romano (2018)
International agency for research on cancer.
J. Higginson (1974)
GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer
J. Ferlay (2013)
The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial
S. Al-Batran (2006)
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement
T. Franchina (2012)
A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer
S. Zeichner (2016)

Semantic Scholar Logo Some data provided by SemanticScholar